Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset

Research output: Contribution to journalReview article

Standard

Genetic Alterations in the Molecular Subtypes of Bladder Cancer : Illustration in the Cancer Genome Atlas Dataset. / Choi, Woonyoung; Ochoa, Andrea; McConkey, David J.; Aine, Mattias; Höglund, Mattias; Kim, William Y.; Real, Francisco X; Kiltie, Anne E.; Milsom, Ian; Dyrskjøt, Lars; Lerner, Seth P.

In: European Urology, Vol. 72, No. 3, 2017, p. 354-365.

Research output: Contribution to journalReview article

Harvard

Choi, W, Ochoa, A, McConkey, DJ, Aine, M, Höglund, M, Kim, WY, Real, FX, Kiltie, AE, Milsom, I, Dyrskjøt, L & Lerner, SP 2017, 'Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset', European Urology, vol. 72, no. 3, pp. 354-365. https://doi.org/10.1016/j.eururo.2017.03.010

APA

CBE

MLA

Vancouver

Author

Choi, Woonyoung ; Ochoa, Andrea ; McConkey, David J. ; Aine, Mattias ; Höglund, Mattias ; Kim, William Y. ; Real, Francisco X ; Kiltie, Anne E. ; Milsom, Ian ; Dyrskjøt, Lars ; Lerner, Seth P. / Genetic Alterations in the Molecular Subtypes of Bladder Cancer : Illustration in the Cancer Genome Atlas Dataset. In: European Urology. 2017 ; Vol. 72, No. 3. pp. 354-365.

RIS

TY - JOUR

T1 - Genetic Alterations in the Molecular Subtypes of Bladder Cancer

T2 - European Urology

AU - Choi, Woonyoung

AU - Ochoa, Andrea

AU - McConkey, David J.

AU - Aine, Mattias

AU - Höglund, Mattias

AU - Kim, William Y.

AU - Real, Francisco X

AU - Kiltie, Anne E.

AU - Milsom, Ian

AU - Dyrskjøt, Lars

AU - Lerner, Seth P.

PY - 2017

Y1 - 2017

N2 - Context: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties. Objective: The availability of comprehensive genomic data from The Cancer Genome Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA alterations with tumor molecular subtype membership. Our overall goal was to determine whether specific DNA mutations and/or copy number variations are enriched in specific molecular subtypes. Evidence: We used the complete TCGA RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them. We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers. Evidence synthesis: The results confirmed that alterations involving RB1 and NFE2L2 were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were enriched in luminal tumors. Conclusions: The results further reinforce the conclusion that the molecular subtypes of bladder cancer are distinct disease entities with specific genetic alterations. Patient summary: Our observation showed that some of subtype-enriched mutations and copy number aberrations are clinically actionable, which has direct implications for the clinical management of patients with bladder cancer. We analyzed the prevalence of the most common genomic alterations in the bladder cancer molecular subtypes. The results have important implications for our understanding of bladder cancer etiology and the development of molecular subtype-specific therapies.

AB - Context: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties. Objective: The availability of comprehensive genomic data from The Cancer Genome Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA alterations with tumor molecular subtype membership. Our overall goal was to determine whether specific DNA mutations and/or copy number variations are enriched in specific molecular subtypes. Evidence: We used the complete TCGA RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them. We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers. Evidence synthesis: The results confirmed that alterations involving RB1 and NFE2L2 were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were enriched in luminal tumors. Conclusions: The results further reinforce the conclusion that the molecular subtypes of bladder cancer are distinct disease entities with specific genetic alterations. Patient summary: Our observation showed that some of subtype-enriched mutations and copy number aberrations are clinically actionable, which has direct implications for the clinical management of patients with bladder cancer. We analyzed the prevalence of the most common genomic alterations in the bladder cancer molecular subtypes. The results have important implications for our understanding of bladder cancer etiology and the development of molecular subtype-specific therapies.

KW - DNA alterations

KW - Molecular subtypes

KW - Muscle-invasive bladder cancer

U2 - 10.1016/j.eururo.2017.03.010

DO - 10.1016/j.eururo.2017.03.010

M3 - Review article

VL - 72

SP - 354

EP - 365

JO - European Urology

JF - European Urology

SN - 1873-7560

IS - 3

ER -